Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLXBiotechnology
+$0.14 today
- Market cap
- $3.42B
- Beta
- -0.16
- P/E (TTM)
- -11.3
- EPS (TTM)
- -$1.36
Volume 1.51M
Average 1.21M
AMLX Debt Repayment
Cash used to repay borrowings during the period.
Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX
Debt Repayment · Q3 FY2026 · quarter ended Sep 2026
Debt repayment grows in line with its trailing trend
Q3 FY2026 debt repayment of $544.61M rose 185.0% year over year, in line with the +185.0% change in trailing-twelve-month debt repayment.
Context
- Debt repayment increased in 0 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +185.0% holds above the trailing-twelve-month pace of +185.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Debt Repayment history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Debt Repayment | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | — |
| FY2024 | 2024-12-31 | 0 | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 25.9M | — |
Debt Repayment vs competitors
How AMLX compares with its peers on the latest reported figures
- Peers report in different currencies, so debt repayment is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +185.0% is the 3rd highest of 6, against a peer median of +50.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $544.61M USD | +185.0% | — | — | |
| LTM Sep 2026 | $483.27M USD | +1181.9% | — | 50.4% | |
| LTM Jun 2026 | $1.38M USD | -96.5% | — | 38.2% | |
| LTM Dec 2025 | CHF 1.03M CHF | +50.2% | +21.7% | 28.7% | |
| LTM Sep 2026 | $832K USD | +949.0% | — | — | |
| LTM Mar 2026 | $90K USD | -99.2% | -41.4% | 67.2% | |
| LTM Mar 2026 | $0 USD | — | — | 0.0% | |
| LTM Mar 2026 | $0 USD | — | — | — | |
| LTM Dec 2025 | $0 USD | — | — | — | |
| LTM Jun 2026 | $0 USD | — | — | — | |
| Peer median (excluding AMLX) | — | +50.2% | -9.9% | 38.2% | |
Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (87.93M) | (198.38M) | 49.27M | (301.74M) | (144.74M) |
| Depreciation & Amortization | 52K | 487K | 1.09M | 904K | 525K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 3.14M | 21.71M | 37.16M | 33.04M | 27.65M |
| Change in Working Capital | 4.6M | (1.64M) | (65.66M) | (45.83M) | (1.08M) |
| Accounts Receivables | (144K) | (15.31M) | (24.74M) | 39.6M | 383K |
| Inventory | 0 | (9.77M) | (73.13M) | (9.25M) | 0 |
| Accounts Payables | 670K | 1.85M | 15.88M | (19.1M) | 580K |
| Other Working Capital | 4.07M | 21.58M | 16.33M | (57.08M) | (2.05M) |
| Other Non-Cash Items | 5.35M | (2.06M) | (9.94M) | 145.99M | (5.7M) |
| Operating Cash Flow | (74.8M) | (179.87M) | 11.92M | (167.65M) | (123.34M) |
| Capital Expenditures | (353K) | (2.53M) | (1.24M) | (157K) | (138K) |
| Acquisitions (Net) | 0 | 236.46M | 0 | 0 | 0 |
| Purchases of Investments | (49.05M) | (415.87M) | (300.83M) | (231.99M) | (231.82M) |
| Sales of Investments | 3M | 179.41M | 394.12M | 344M | 246M |
| Other Investing Activities | 0 | (236.46M) | 0 | (36.2M) | 0 |
| Investing Cash Flow | (46.41M) | (238.99M) | 92.05M | 75.65M | 14.04M |
| Debt Repayment | 25.9M | 0 | 0 | 0 | 0 |
| Common Stock Issued | 0 | 432.45M | 6.86M | 2.13M | 260.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2.39M) | (658K) | (3.32M) | (1.78M) | (3.36M) |
| Financing Cash Flow | 158.51M | 431.79M | 3.54M | 348K | 257.03M |
| Effect of Forex Changes | 13K | (65K) | 160K | (438K) | 1.07M |
| Net Change in Cash | 37.31M | 12.87M | 107.68M | (92.08M) | 148.8M |
| Free Cash Flow | (75.15M) | (182.4M) | 10.68M | (167.8M) | (123.48M) |
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
Intrinsic Alpha fair value
Locked
Current Price
$26.62
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.